JPMorgan Upgrades Apellis Pharmaceuticals (APLS) to Overweight on 'Return To Growth'
Tweet Send to a Friend
(Updated - October 6, 2023 6:34 AM EDT)
JPMorgan analyst Anupam Rama upgraded Apellis Pharmaceuticals (NASDAQ: APLS) from Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
JPMorgan analyst Anupam Rama upgraded Apellis Pharmaceuticals (NASDAQ: APLS) from Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
